Stock of the Day

FibroGen (FGEN)

$0.71

-$0.07 (-8.6%)

Market Cap: $77.83M

About FibroGen

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.

The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Recent News

• FibroGen to sell China business, extend cash runway to focus on cancer drugs (bizjournals.com)
• FibroGen stock soars on China unit sale (in.investing.com)
• This Small Cap Soared Following Subsidiary Sale Announcement Worth $160M (msn.com)
• FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million (finance.yahoo.com)
• FibroGen China sale ‘shrewd strategic transaction,’ says H.C. Wainwright (markets.businessinsider.com)
• FibroGen sells China unit to AstraZeneca in deal worth $160 million (reuters.com)
• FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million (globenewswire.com)